Treatment of IOH and risk of visual complications.
Hayreh
Sohan Singh
SS
D020757:Amaurosis Fugax / Q000139:chemically induced; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D003971:Diastole / Q000187:drug effects; D004334:Drug Administration Schedule; D005901:Glaucoma / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology / Q000523:psychology; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009819:Office Visits; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000150:complications; D015995:Prevalence; D013599:Systole / Q000187:drug effects; D014786:Vision Disorders / Q000139:chemically induced* / Q000453:epidemiology / Q000503:physiopathology
D000959:Antihypertensive Agents